News

Tonix Pharmaceuticals (TNXP) – A Broad Pipeline With Many Product Milestones Ahead

Health
0 min read

Monday, April 18, 2022

Tonix Pharmaceuticals (TNXP)
A Broad Pipeline With Many Product Milestones Ahead

Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company. The company is engaged in discovering, licensing, acquiring and developing drugs and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes biologics to prevent infectious diseases and small molecules and biologics to treat pain, psychiatric and addiction conditions. While the company is also developing a potential vaccine to protect against the novel coronavirus disease. Its main products are used for treating fibromyalgia, or FM, and posttraumatic stress disorder, or PTSD.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating Coverage With An Outperform Rating.  Tonix has developed a pipeline of products in Immunology, CNS, and Infectious Diseases. Several pipeline products are expected to reach clinical milestones or data announcements over the next 12 months, including the Phase 3 RESILIANT trial in fibromyalgia.

    The Phase 3 RESILIANT Trial Is Underway.  Tonix has started patient enrollment in the Phase 3 RESILIANT trial, testing TNX-102 SL in fibromyalgia. The previous Phase 3 RELIEF trial met its primary endpoint, and if successful, RESILIANT would give Tonix the two trials needed to apply for FDA approval. An interim analysis has been scheduled for 1Q23 …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.